Lareb notes newly reported deaths shortly after vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a total of 15 reports so far regarding deaths shortly after receiving the COVID-19 vaccinations.
New research in GGD test lanes on spread of coronavirus SARS-CoV-2 RIVM is launching a survey-based study this week on risk factors for the coronavirus SARS-CoV-2. The participants in this study are people who get tested for COVID-19 in a GGD test lane.
80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Tracking down sources of disease outbreaks like Sherlock Holmes. 'I want to know the story behind an epidemic'. Interview with Jaap van Dissel, Director of RIVM Centre for Infectious Disease Control.
Cervical cancer screening in the Netherlands January 19 - 25 European Cervical Cancer Prevention Week.
State of infectious diseases in The Netherlands RIVM report 'State of Infectious Diseases 2012' provides insight into the development of infectious diseases in The Netherlands.